Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17100674 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | November 2020 | May 2025 | Abandon | 54 | 4 | 0 | No | No |
| 17079553 | NMDA ANTAGONIST PRODRUGS | October 2020 | December 2023 | Allow | 38 | 3 | 0 | No | No |
| 15518069 | ANTI-TAU ANTIBODY AND USES THEREOF | April 2017 | May 2018 | Allow | 24 | 1 | 0 | Yes | No |
| 15389286 | HUMANIZED ANTI-TAU(PS422) ANTIBODIES AND METHODS OF USE | December 2016 | November 2018 | Allow | 23 | 2 | 1 | Yes | No |
| 15306466 | SYNTHETIC HAPTEN CARRIER COMPOSITIONS AND METHODS | October 2016 | June 2018 | Allow | 20 | 1 | 0 | Yes | No |
| 15266812 | PCSK9 VACCINE | September 2016 | February 2018 | Allow | 17 | 1 | 0 | Yes | No |
| 15246232 | PEPTIDE-MEDIATED DELIVERY OF IMMUNOGLOBULINS ACROSS THE BLOOD-BRAIN BARRIER | August 2016 | May 2018 | Allow | 20 | 1 | 0 | No | No |
| 15111248 | NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE | July 2016 | March 2018 | Allow | 20 | 1 | 0 | No | No |
| 15180031 | MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF | June 2016 | June 2018 | Allow | 24 | 3 | 0 | Yes | No |
| 15099860 | BRAIN PERMEANT PEPTIDOMIMETIC BETA-SECRETASE 1 INHIBITORS FOR THE TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL DISORDERS OR CONDITIONS | April 2016 | November 2017 | Allow | 19 | 1 | 1 | No | No |
| 15090328 | PROTOXIN-II VARIANTS AND METHODS OF USE | April 2016 | December 2018 | Allow | 32 | 4 | 1 | Yes | No |
| 14890292 | COMPOUNDS SUITABLE FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS AS WELL AS METHODS FOR THE DIAGNOSIS/PROGNOSIS OF MYELOPROLIFERATIVE NEOPLASMS | November 2015 | November 2018 | Allow | 37 | 2 | 1 | Yes | No |
| 14929449 | USE OF THE PAT NONAPEPTIDE IN THE TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | November 2015 | June 2016 | Allow | 8 | 1 | 0 | Yes | No |
| 14822711 | MODULATION OF AXON DEGENERATION | August 2015 | November 2017 | Allow | 28 | 1 | 1 | No | No |
| 14648834 | CYCLIC PEPTIDE AND PHARMACEUTICAL PRODUCT CONTAINING SAME | June 2015 | April 2017 | Allow | 23 | 1 | 0 | No | No |
| 14508977 | PCSK9 VACCINE | October 2014 | June 2016 | Allow | 20 | 1 | 1 | Yes | No |
| 14384685 | MODIFIED KISSPEPTIN PEPTIDES AND USES THEREOF | September 2014 | March 2016 | Allow | 18 | 1 | 0 | Yes | No |
| 14302992 | NEUROPROTECTION BY HEPATIC CELLS AND HEPATOCYTE SECRETORY FACTORS | June 2014 | April 2015 | Allow | 10 | 1 | 0 | Yes | No |
| 14118988 | COMPOSITIONS AND METHODS FOR CONTROLLING NEURONAL EXCITATION | March 2014 | June 2016 | Allow | 31 | 1 | 1 | No | No |
| 14103893 | Compounds as antagonists or inverse agonists of opioid receptors for treatment of addiction | December 2013 | April 2014 | Allow | 4 | 0 | 0 | No | No |
| 13936084 | Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System | July 2013 | July 2014 | Allow | 13 | 1 | 1 | Yes | No |
| 13809805 | USE OF THE PAT NANOPEPTIDE IN TREATING AND PREVENTING NEURODEGENERATIVE DISEASES | January 2013 | July 2015 | Allow | 30 | 3 | 0 | Yes | No |
| 13601034 | Methods for Altering MRNA Splicing and Treating Familial Dysautonomia by Administering Kinetin, Benzyladenine, and Tocotrienols | August 2012 | January 2014 | Allow | 16 | 1 | 1 | Yes | No |
| 13394068 | KLF FAMILY MEMBERS REGULATE INTRINSIC AXON REGENERATION ABILITY | May 2012 | August 2013 | Allow | 17 | 1 | 0 | No | No |
| 13467661 | BIOMARKERS FOR THE DETECTION AND SCREENING OF DOWN SYNDROME | May 2012 | July 2013 | Allow | 14 | 1 | 0 | No | No |
| 13462965 | NEUROPROTECTION BY HEPATIC CELLS AND HEPATOCYTE SECRETORY FACTORS | May 2012 | February 2014 | Allow | 21 | 1 | 1 | Yes | No |
| 13458609 | ANTIBODIES SELECTIVE FOR PATHOLOGICAL TAU DIMERS AND PREFIBRILLAR PATHOLOGICAL TAU OLIGOMERS AND THEIR USES IN TREATMENT, DIAGNOSIS AND MONITORING OF TAUOPATHIES | April 2012 | October 2013 | Allow | 18 | 1 | 0 | No | No |
| 13441879 | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists | April 2012 | December 2014 | Abandon | 32 | 3 | 0 | Yes | No |
| 13406289 | MODULATING NEUROMUSCULAR JUNCTION DENSITY CHANGES IN BOTULINUM-TOXIN TREATED TISSUE | February 2012 | March 2014 | Allow | 25 | 2 | 0 | Yes | No |
| 13131231 | Use of DR6 and p75 Antagonists to Promote Survival of Cells of the Nervous System | February 2012 | March 2013 | Allow | 22 | 0 | 1 | No | No |
| 13265242 | INHIBITION OF PRION PROPAGATION BY RECEPTOR ASSOCIATED PROTEIN (RAP), ITS DERIVATIVES, MIMETICS AND SYNTHETIC PEPTIDES | January 2012 | April 2015 | Allow | 42 | 5 | 0 | Yes | No |
| 12672013 | ATF4 INHIBITORS AND THEIR USE FOR NEURAL PROTECTION, REPAIR, REGENERATION, AND PLASTICITY | August 2011 | January 2015 | Allow | 59 | 2 | 1 | No | No |
| 13125333 | Modulation of Axon Degeneration | June 2011 | March 2015 | Allow | 47 | 4 | 1 | Yes | No |
| 12733096 | METHOD OF SCREENING COMPOUNDS USING CALHM (FAM26C) | February 2011 | December 2012 | Allow | 34 | 0 | 1 | No | No |
| 12669776 | TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN | May 2010 | March 2013 | Allow | 38 | 1 | 1 | No | No |
| 12776920 | LEUKEMIC CELL CNS INFILTRATION CONTROLLED BY NOTCH-INDUCED CHEMOTAXIS | May 2010 | March 2015 | Allow | 59 | 3 | 1 | Yes | No |
| 12376580 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | February 2009 | September 2013 | Allow | 56 | 2 | 1 | No | No |
| 11792758 | Methods and Compositions for Monitoring Progression Of Huntington's Disease | May 2008 | June 2013 | Allow | 60 | 3 | 0 | No | No |
| 11955490 | PREPARATION AND APPLICATION OF BIODEGRADABLE-MATERIAL-MADE MICROSPHERE VASCULAR EMBOLUS CONTAINING LIPOSOME-ENCAPSULATED CYTOKINES | December 2007 | March 2013 | Allow | 60 | 5 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner WEIDNER, ADAM M works in Art Unit 1651 and has examined 39 patent applications in our dataset. With an allowance rate of 94.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 24 months.
Examiner WEIDNER, ADAM M's allowance rate of 94.9% places them in the 83% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by WEIDNER, ADAM M receive 1.79 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by WEIDNER, ADAM M is 24 months. This places the examiner in the 80% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +0.8% benefit to allowance rate for applications examined by WEIDNER, ADAM M. This interview benefit is in the 20% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 30.6% of applications are subsequently allowed. This success rate is in the 63% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 55.6% of cases where such amendments are filed. This entry rate is in the 82% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 50.0% are granted (fully or in part). This grant rate is in the 44% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.4% of allowed cases (in the 83% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.